Uterine Fibroid Drugs Market Set to Reach US$ 12.8 Billion by 2035 | Astute Analytica

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Sumitomo Pharma expects to receive a significant US$ 100 million sales milestone payment from Pfizer in the upcoming fiscal year

  80% confidence

• Sumitomo forecasts a core operating profit of JPY 56 billion for FY2025

  80% confidence

• The global uterine fibroid drugs market was valued at US$ 3.8 billion in 2025 and is expected to reach US$ 12.8 billion by 2035, growing at a CAGR of 14.4% during the forecast period 2026–2035

  80% confidence

• Clinical efficacy data showing 78 percent blood loss reduction

  80% confidence

• Their immunology division generated US$ 26.682 billion

  80% confidence

• Sumitomo Pharma recorded a JPY 1.6 billion gain in Q3 FY2024 specifically from equity transfers

  80% confidence

• AbbVie issued confident 2025 adjusted diluted EPS guidance between US$ 12.12 and US$ 12.32

  80% confidence

• AbbVie reaffirms a high single-digit compound annual revenue growth rate for its ex-Humira platform through 2029

  80% confidence

• The company expects a JPY 19.9 billion revenue increase from Orgovyx

  80% confidence

• The global age-standardized incidence rate reached 250.93 per 100,000 in the 2025 reporting period

  80% confidence

• Myfembree revenue is expected to remain flat in FY2025 during the sales model transition

  80% confidence

• Sumitomo Pharma's revised revenue forecast for its North American segment is JPY 248.2 billion for the fiscal year ending March 2025

  80% confidence

• AbbVie expects combined sales of its immunology duo to exceed US$ 27 billion in 2027

  80% confidence

• Sumitomo Pharma projects FY2025 revenue to reach JPY 429 billion based on the October 2025 revised forecast

  80% confidence

• 25% to 50% of symptomatic women fall into the critical 30-50 age bracket

  80% confidence

• The company forecasts JPY 28.8 billion in operating profit for the fiscal year ending March 2025

  80% confidence

• A comprehensive 2024 analysis estimates the total annual economic burden of uterine fibroids in the US at up to US$ 41.4 billion

  80% confidence

• Sumitomo Pharma reported a volume underperformance of US$ 37 million for Myfembree in the U.S. for the period ending December 2024

  80% confidence

• Sumitomo projects JPY 98.9 billion in net profit attributable to owners for the half-year ended September 30, 2025

  80% confidence

• Kissei's 2025 forecast includes a JPY 13.2 billion upward revision in core operating profit

  80% confidence

• AbbVie reported substantial full-year 2024 net revenues of US$ 56.334 billion

  80% confidence

• Sumitomo has allocated JPY 13 billion for R&D expenses in FY2025

  80% confidence

• Approximately 80% of women with fibroids may be asymptomatic

  80% confidence